| (Values in U.S. Thousands) | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 | Mar, 2021 |
| Sales | -68,312 | 63,745 | -23,978 | 33,704 | 90,658 |
| Sales Growth | -207.16% | +365.85% | -171.14% | -62.82% | +165.21% |
| Net Income | -143,160 | 3,788 | -56,018 | 8,838 | 53,158 |
| Net Income Growth | -3,879.30% | +106.76% | -733.83% | -83.37% | +127.18% |
Syncona Limited (SYNC.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Syncona Ltd is a closed-ended investment company in the United Kingdom. Its investment objective is to achieve superior long-term capital appreciation from its investments. The company invests in life science businesses (including private and quoted companies) and single or multi-asset projects (Life Science Investments).
Fiscal Year End Date: 03/31